Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
Reporting Adverse Events or Safety Concerns If you experience or suspect an adverse event, contamination, or quality issue with this product, report it immediately to: Hospira Pfizer: Manufacturer contact information available on the product vial FDA MedWatch: 1-888-SAFEMED (1-888-723-3633) or online at fda.gov/medwatch Poison Control: 1-800-222-1222 (for toxicology guidance) Your institutional pharmacovigilance system: If you work for a hospital, clinic, or healthcare institution Regulatory Compliance By purchasing and using this product, you agree to comply with all applicable FDA regulations, state pharmacy laws, and professional licensing requirements
The real-world control cohort consisted of individuals with no GLP-1 medication history who still engaged with the healthcare system to a comparable extent, as marked by outpatient encounters and a history of medication use
We need large-scale, long-duration trials with direct muscle function measurements to draw firm conclusions across broader patient populations, including those with sarcopenia, cachexia, or heart disease
